Breast cancer risk and hormone replacement therapy
Breast cancer risk and hormone replacement therapy
RR of breast cancer according to the duration of use within categories of time since the last use of hormone replacement therapy. The RR of breast cancer in this analysis of data from 51 epidemiologic studies was highest among women who were current or recent (within five years) users of ERT and had the longest duration of use compared with never users. The RR of developing cancer was 1.35 for women who were current ERT users and had taken hormones for five years or longer.
ERT: estrogen replacement therapy; RR: relative risk. * Relative to never-users, stratified by study, age at diagnosis, time since menopause, body-mass index, parity, and the age a woman was when her first child was born. "Last use <5 years before diagnosis" includes current users.